日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

对既往接受过治疗的转移性乳腺癌患者进行奈拉替尼联合卡培他滨与拉帕替尼联合卡培他滨治疗的III期NALA研究的生物标志物分析

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-1584
Saura, Cristina; Matito, Judit; Oliveira, Mafalda; Wildiers, Hans; Brufksy, Adam M; Waters, Simon H; Hurvitz, Sara A; Moy, Beverly; Kim, Sung-Bae; Gradishar, William J; Queiroz, Geraldo Silva; Cronemberger, Eduardo; Wallweber, Gerald J; Bebchuk, Judith; Keyvanjah, Kiana; Lalani, Alshad S; Bryce, Richard; Vivancos, Ana; Eli, Lisa D; Delaloge, Suzette
肿瘤
肿瘤免疫
乳腺癌
发表日期：2021
文献求助 收藏

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

NALA试验中，奈拉替尼联合卡培他滨治疗中枢神经系统受累患者亚组的疗效

期刊:Oncologist
影响因子:4.2
doi:10.1002/onco.13830
Hurvitz, Sara A; Saura, Cristina; Oliveira, Mafalda; Trudeau, Maureen E; Moy, Beverly; Delaloge, Suzette; Gradishar, William; Kim, Sung-Bae; Haley, Barbara; Ryvo, Larisa; Dai, Ming-Shen; Milovanov, Vladimir; Alarcón, Jesús; Kalmadi, Sujith; Cronemberger, Eduardo; Souza, Cristiano; Landeiro, Luciana; Bose, Ron; Bebchuk, Judith; Kabbinavar, Fairooz; Bryce, Richard; Keyvanjah, Kiana; Brufsky, Adam M
神经科学
发表日期：2021
文献求助 收藏

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

奈拉替尼联合卡培他滨可维持HER2阳性转移性乳腺癌患者（既往接受过≥2种HER2靶向治疗方案）的健康相关生活质量。

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-021-06217-4
Moy, Beverly; Oliveira, Mafalda; Saura, Cristina; Gradishar, William; Kim, Sung-Bae; Brufsky, Adam; Hurvitz, Sara A; Ryvo, Larisa; Fagnani, Daniele; Kalmadi, Sujith; Silverman, Paula; Delaloge, Suzette; Alarcon, Jesus; Kwong, Ava; Lee, Keun Seok; Ang, Peter Cher Siang; Ow, Samuel Guan Wei; Chu, Sung-Chao; Bryce, Richard; Keyvanjah, Kiana; Bebchuk, Judith; Zhang, Bo; Oestreicher, Nina; Bose, Ron; Chan, Nancy
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2021
文献求助 收藏

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

在既往接受过≥2种HER2靶向方案治疗的HER2阳性转移性乳腺癌患者中，奈拉替尼联合卡培他滨对比拉帕替尼联合卡培他滨：III期NALA试验

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.20.00147
Saura, Cristina; Oliveira, Mafalda; Feng, Yin-Hsun; Dai, Ming-Shen; Chen, Shang-Wen; Hurvitz, Sara A; Kim, Sung-Bae; Moy, Beverly; Delaloge, Suzette; Gradishar, William; Masuda, Norikazu; Palacova, Marketa; Trudeau, Maureen E; Mattson, Johanna; Yap, Yoon Sim; Hou, Ming-Feng; De Laurentiis, Michelino; Yeh, Yu-Min; Chang, Hong-Tai; Yau, Thomas; Wildiers, Hans; Haley, Barbara; Fagnani, Daniele; Lu, Yen-Shen; Crown, John; Lin, Johnson; Takahashi, Masato; Takano, Toshimi; Yamaguchi, Miki; Fujii, Takaaki; Yao, Bin; Bebchuk, Judith; Keyvanjah, Kiana; Bryce, Richard; Brufsky, Adam
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2020
文献求助 收藏

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

奈拉替尼治疗HER2突变型转移性宫颈癌患者：来自2期SUMMIT篮式试验的结果

期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2020.07.025
Oaknin, Ana; Friedman, Claire F; Roman, Lynda D; D'Souza, Anishka; Brana, Irene; Bidard, François-Clement; Goldman, Jonathan; Alvarez, Edwin A; Boni, Valentina; ElNaggar, Adam C; Passalacqua, Rodolfo; Do, Khanh T M; Santin, Alessandro D; Keyvanjah, Kiana; Xu, Feng; Eli, Lisa D; Lalani, Alshad S; Bryce, Richard P; Hyman, David M; Meric-Bernstam, Funda; Solit, David B; Monk, Bradley J
肿瘤
肿瘤免疫
HER2
多发性骨髓瘤
宫颈癌
发表日期：2020
文献求助 收藏

LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma

采用液相色谱-串联质谱法定量分析人血浆中的酪氨酸激酶抑制剂奈拉替尼

期刊:Journal of Pharmaceutical and Biomedical Analysis
影响因子:3.1
doi:10.1016/j.jpba.2016.11.035
Kiesel, Brian F; Parise, Robert A; Wong, Alvin; Keyvanjah, Kiana; Jacobs, Samuel; Beumer, Jan H
信号转导
发表日期：2017
文献求助 收藏

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

可溶性KIT与接受舒尼替尼治疗的转移性乳腺癌患者的临床结果相关

期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/1479-5876-10-165
Keyvanjah, Kiana; DePrimo, Samuel E; Harmon, Charles S; Huang, Xin; Kern, Kenneth A; Carley, William
肿瘤
KIT
乳腺癌
肿瘤免疫
发表日期：2012
文献求助 收藏